Consensus guidelines for the management and treatment of neuroendocrine tumors Journal Article
| Authors: | Kunz, P. L.; Reidy-Lagunes, D.; Anthony, L. B.; Bertino, E. M.; Brendtro, K.; Chan, J. A.; Chen, H.; Jensen, R. T.; Kim, M. K.; Klimstra, D. S.; Kulke, M. H.; Liu, E. H.; Metz, D. C.; Phan, A. T.; Sippel, R. S.; Strosberg, J. R.; Yao, J. C. |
| Article Title: | Consensus guidelines for the management and treatment of neuroendocrine tumors |
| Abstract: | ABSTRACT: Neuroendocrine tumors are a heterogeneous group of tumors originating in various anatomic locations. The management of this disease poses a significant challenge because of the heterogeneous clinical presentations and varying degrees of aggressiveness. The recent completion of several phase 3 trials, including those evaluating octreotide, sunitinib, and everolimus, demonstrate that rigorous evaluation of novel agents in this disease is possible and can lead to practice-changing outcomes. Nevertheless, there are many aspects to the treatment of neuroendocrine tumors that remain unclear and controversial. The North American Neuroendocrine Tumor Society published a set of consensus guidelines in 2010, which provided an overview for the treatment of patients with these malignancies. Here, we present a set of consensus tables intended to complement these guidelines and serve as a quick, accessible reference for the practicing physician. Copyright © 2013 Lippincott Williams & Wilkins. |
| Keywords: | immunohistochemistry; cancer chemotherapy; cancer survival; primary tumor; overall survival; sunitinib; advanced cancer; drug efficacy; follow up; lymph node dissection; pancreaticoduodenectomy; protein blood level; dexamethasone; practice guideline; tumor biopsy; neuroendocrine tumor; proton pump inhibitor; endoscopic surgery; mitosis rate; carcinoid; octreotide; pheochromocytoma; hemicolectomy; cancer scintiscanning; everolimus; pentetreotide in 111; neuroendocrine tumors; insulinoma; steroid therapy; randomized controlled trial (topic); 5 hydroxyindoleacetic acid; chromogranin a; phase 3 clinical trial (topic); carcinoid syndrome; corticotropin; gastrinoma; pancreatic neuroendocrine tumor; diazoxide; neuroendocrine/diagnosis; neuroendocrine/pathology; neuroendocrine/treatment |
| Journal Title: | Pancreas |
| Volume: | 42 |
| Issue: | 4 |
| ISSN: | 0885-3177 |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2013-05-01 |
| Start Page: | 557 |
| End Page: | 577 |
| Language: | English |
| DOI: | 10.1097/MPA.0b013e31828e34a4 |
| PROVIDER: | scopus |
| PUBMED: | 23591432 |
| PMCID: | PMC4304762 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 3 June 2013" - "CODEN: PANCE" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work